Vaxart (OTCMKTS:VXRT) Issues Quarterly Earnings Results

Vaxart (OTCMKTS:VXRT) posted its earnings results on Thursday. The biotechnology company reported $0.02 EPS for the quarter, meeting analysts’ consensus estimates of $0.02, Zacks reports. Vaxart had a return on equity of 75.49% and a net margin of 14.51%.The company had revenue of $39.23 million for the quarter, compared to the consensus estimate of $65.50 million.

Vaxart Trading Down 5.4%

VXRT traded down $0.04 during trading hours on Friday, hitting $0.70. 691,277 shares of the company’s stock were exchanged, compared to its average volume of 433,090. Vaxart has a 12-month low of $0.26 and a 12-month high of $0.84. The firm has a 50 day moving average of $0.70 and a 200 day moving average of $0.54. The firm has a market cap of $169.38 million, a P/E ratio of 4.67 and a beta of 1.18.

Institutional Investors Weigh In On Vaxart

Large investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. acquired a new position in Vaxart during the 1st quarter worth approximately $31,000. Creative Planning acquired a new position in Vaxart during the 2nd quarter worth approximately $33,000. Invesco Ltd. grew its holdings in Vaxart by 93.1% during the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock worth $60,000 after acquiring an additional 70,568 shares in the last quarter. Raymond James Financial Inc. grew its holdings in Vaxart by 16.9% during the 2nd quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock worth $107,000 after acquiring an additional 34,075 shares in the last quarter. Finally, Jones Financial Companies Lllp grew its holdings in Vaxart by 276,364.7% during the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock worth $196,000 after acquiring an additional 478,111 shares in the last quarter. 18.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised Vaxart to a “buy” rating in a research report on Friday, January 23rd.

Vaxart Company Profile

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.